Peptides for TBI (Traumatic Brain Injury): Semax, BPC-157, and Cerebrolysin

Traumatic brain injury (TBI) causes an immediate primary injury from mechanical forces followed by a protracted secondary injury cascade—neuroinflammation, excitotoxicity, oxidative stress, and blood-brain barrier disruption that unfolds over hours to months. Current standard of care addresses the primary injury (surgical decompression when needed, intracranial pressure management) but has limited tools for modifying the secondary injury cascade. Neuroprotective and neuroregenerative peptides represent an emerging approach to this secondary injury phase.

Secondary Injury: The Therapeutic Window

The secondary injury cascade creates a biological window for intervention. Within hours of TBI, glutamate-mediated excitotoxicity damages neurons, inflammatory microglia release cytotoxic cytokines, mitochondrial dysfunction impairs energy production, and blood-brain barrier breakdown allows immune cells to infiltrate the normally protected brain parenchyma.

This cascade continues for days to months—brain swelling, progressive white matter damage, and neuronal apoptosis occur long after the initial trauma. Peptides that attenuate neuroinflammation, support mitochondrial function, promote neurotrophic signaling, and accelerate repair can intervene at multiple points in this cascade.

Semax: BDNF Amplification for Neuroprotection

Semax is a heptapeptide (ACTH 4-7 Pro8Gly9Pro10) derived from ACTH that dramatically upregulates brain-derived neurotrophic factor (BDNF) and nerve growth factor (NGF). BDNF is the primary survival and plasticity factor for neurons—it promotes neuronal survival, enhances synaptic plasticity, and stimulates neurogenesis in the hippocampus.

In Russian clinical use, Semax is an approved treatment for stroke and brain injury, used at 300-900 mcg intranasally per day. The intranasal route allows direct delivery to the olfactory nerve and rapid transport into brain tissue, bypassing the blood-brain barrier. Human data from stroke trials shows reduced ischemic lesion volume and improved functional outcomes with Semax treatment.

For TBI, the mechanisms are directly applicable: BDNF upregulation protects surviving neurons, promotes axonal sprouting, and supports the neuroplastic adaptations needed for functional recovery. Semax also reduces neuroinflammatory cytokines including TNF-alpha and IL-1beta that drive secondary injury.

BPC-157: Reducing Neuroinflammation and Supporting Repair

BPC-157 has documented neuroprotective effects in multiple animal models of brain injury. In a rat model of traumatic brain injury via controlled cortical impact, BPC-157 treatment reduced the behavioral deficits associated with injury, reduced brain edema, and decreased inflammatory markers in brain tissue.

Its mechanisms in TBI are: reduction of glutamate excitotoxicity (BPC-157 modulates GABAergic and dopaminergic signaling), anti-neuroinflammatory effects through COX pathway modulation, restoration of blood-brain barrier integrity through tight junction protein upregulation, and direct neuroprotection through nitric oxide-dependent mechanisms.

BPC-157 also interacts with the gut-brain axis—the vagus nerve connection between GI health and brain function. Post-TBI gut dysfunction is common and worsens brain outcomes; BPC-157's gastroprotective effects support this pathway bidirectionally.

Dosing: 500 mcg/day subcutaneously or 500 mcg-1 mg orally. Starting within the first 24-72 hours after TBI provides the greatest neuroprotective benefit, though delayed initiation during the subacute phase (days to weeks post-injury) still influences neuroinflammation and repair.

Cerebrolysin: Neurotrophic Peptide Mixture

Cerebrolysin is a neuropeptide preparation derived from porcine brain tissue—it contains a complex mixture of low-molecular-weight neurotrophic peptides including BDNF, NGF, CNTF, and GDNF fragments. It has more human clinical trial data than any other neuropeptide intervention for TBI, including multiple randomized controlled trials.

A systematic review of Cerebrolysin in TBI showed consistent improvement in neurological recovery scores compared to placebo, with effects on both acute neuroprotection (reducing secondary injury) and subacute neuroplasticity (improving functional recovery). It is approved for brain injury in multiple countries and commonly used in Eastern European and Asian neurology practices.

Dosing in clinical trials: 10-50 mL IV daily for 10-21 days during acute/subacute phase. Maintenance dosing with smaller IM injections is used in chronic TBI recovery. Access in the US requires compounding pharmacy sources or international travel.

Selank and Dihexa for Cognitive Recovery

Selank (a synthetic analog of Tuftsin) has anxiolytic and cognitive-enhancing effects through modulation of GABA-A receptors and increased BDNF expression. In TBI recovery, anxiety and cognitive dysfunction (memory, processing speed, attention) are common persistent symptoms. Selank addresses both. Dihexa amplifies HGF/MET signaling to promote synaptogenesis—the formation of new synaptic connections that underlies cognitive recovery after brain injury.

FAQ

Can peptides help with chronic TBI symptoms (months or years post-injury)? Yes. Neuroplasticity and partial recovery continue for years after TBI. Neurotrophic peptides like Semax and Cerebrolysin support ongoing synaptic remodeling and can improve cognitive function even in chronic TBI. The improvement trajectory is slower and less dramatic than in the acute phase, but meaningful gains are documented in the literature.

Is intranasal delivery of Semax sufficient for brain penetration? Yes. Intranasal delivery allows Semax to reach the olfactory nerve and enter the olfactory bulb directly, from which neurotrophic signaling distributes throughout the brain. Studies confirm significant CNS bioavailability via this route. It is the preferred route for Semax specifically because it is non-invasive and effective.

Are there risks to combining multiple neuroprotective peptides after TBI? The peptides described have non-overlapping primary mechanisms and there are no documented adverse interactions. The main practical consideration is that some (like Semax) can cause mild activation or anxiety in sensitive individuals at higher doses, and those with TBI may be neurologically sensitive. Starting with lower doses and titrating upward is prudent.

Related Articles

• Afamelanotide: FDA-Approved Melanocyte Peptide
• AOD-9604: HGH Fragment for Fat Loss
• Argireline: The Topical Peptide Alternative to Botox?
• Bacteriostatic Water for Peptides: Why It Matters and How to Use It
• Best Peptide Stacks for Recovery, Fat Loss, and Longevity

Track your supplements in Optimize.